Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults

Novo Nordisk's (NVO) fast-acting mealtime insulin aspart, Fiasp, has been approved by the FDA for the treatment of adults with diabetes.

    Lilly (LLY) Makes Leadership Changes to Executive Positions

    Eli Lilly and Company (LLY) makes some executive appointments for various departments.

      Is Biogen Inc. (BIIB) a Great Stock for Value Investors?

      Lets put Biogen Inc.(BIIB) stock into this equation and find out if it is a good choice for value-oriented investors right now.

        AbbVie Submits NDA for Endometriosis Candidate to the FDA

        AbbVie Inc. (ABBV) and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA.

          Novartis' (NVS) MS Drug Gilenya Positive in Long-Term Study

          Novartis AG (NVS) announced positive top-line results from the phase III study, PARADIGMS on MS Drug Gilenya for children and adolescents.

            Biogen Alzheimer's Drug Shows Promise in Long-Term Study

            Biogen (BIIB) announced data from a long-term study on its Alzheimer's disease candidate, aducanumab, which showed continued benefit in the rate of amyloid decline.

              Company News For August 29, 2017

              Companies in the news are: EXPE,BIIB,GILD,KITE,JNJ

                Biogen's Humira Biosimilar Imraldi Gets Approval in EU

                Biogen Inc.'s (BIIB) biosimilar version of AbbVie's top-selling blockbuster drug, Humira has been approved by the European Commission.

                  Kevin Cook headshot

                  What You See, and What You Get: The Neurology of Perception

                  While "the biotech century" cures cancer, it's also tackling dozens of neurological diseases investors should learn about.

                    The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix

                    The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix

                      PDL BioPharma (PDLI) Q2 Earnings Beat, Revenues Rise Y/Y

                      PDL BioPharma's (PDLI) earnings surpass expectations. Revenues also significantly increase year over year, thanks to a rise in fair value of the Depomed royalty asset.

                        Is a Beat in Store for Ionis (IONS) This Earnings Season?

                        Ionis Pharmaceuticals, Inc. (IONS) received marketing approval in the EU for spinal muscular atrophy and its launch is expected to further grow sales in Q2.

                          Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line

                          Acorda's (ACOR) dismal performance in Q2 significantly misses earnings expectations. However, the company's revenues met estimates on the back of strong Ampyra sales.

                            Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up

                            Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.

                              Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed

                              Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares.

                                Biogen (BIIB) Tops Q2 Earnings and Revenue

                                Biogen (BIIB) reported better-than expected earnings in the second quarter of 2017 with revenue beating estimates.

                                  Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?

                                  At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.

                                    Mark Vickery headshot

                                    Top Stock Reports for Boeing, AbbVie & U.S. Bancorp

                                    Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), AbbVie (ABBV), and U.S. Bancorp (USB).

                                      Arpita Dutt headshot

                                      Better Days Ahead for the Pharma Sector?

                                      Sales, R&D, strong results, and a higher number of FDA approvals.

                                        Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why

                                        Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.

                                          Kevin Cook headshot

                                          Bear of the Day: Bioverativ (BIVV)

                                          Biogen spin-off just reported its first quarter and made an acquisition, but estimates were trimmed

                                            Biogen Loses Top Executive Again, CFO Clancy to Join Alexion

                                            Biogen Inc.'s (BIIB) chief financial officer (CFO) for the last 10 years, Paul Clancy, is joining Alexion Pharmaceuticals, Inc. (ALXN) next month.

                                              Biogen/Ionis Spinraza Granted Marketing Authorization in EU

                                              Biogen Inc. (BIIB) announced granting of marketing authorization to its marketed drug Spinraza (nusinersen) by European Commission under the accelerated assessment program for treating patients with 5q spinal muscular atrophy.

                                                Arpita Dutt headshot

                                                5 Drug Stocks in Focus on World MS Day

                                                Life with MS -- this world MS day, here's a look at 5 stocks including Biogen (BIIB) that are key players in the multiple sclerosis (MS) market.

                                                  The Zacks Analyst Blog Highlights: UnitedHealth Group, Union Pacific, Biogen, United Technologies and Accenture

                                                  The Zacks Analyst Blog Highlights: UnitedHealth Group, Union Pacific, Biogen, United Technologies and Accenture